PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance
EIK1001-008
Phase 2 small_molecule active
Quick answer
PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance for Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Eikon Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eikon Therapeutics
- Indication
- Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active